According to J.P. Morgan, Charles River Laboratories CRL 1Q results were generally soft (net sales -2.2% y/y), but showed q/q improvement (+1.5% q/q) against diminished expectations (consensus $279M), with cost initiatives and share repurchases providing cushion on the bottom line.
J.P. Morgan said that, “Despite cautious optimism around the preclinical services market, we continue to believe that there is still risk around further pharma R&D cuts and margins, given overcapacity among both CROs and pharma, and accordingly, we remain Neutral on CRL shares.”
Charles River Laboratories closed yesterday at $41.52.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsCharles River LaboratoriesHealth CareJ.P. MorganLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in